KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Short-term Investments (2017 - 2026)

Moderna (MRNA) has disclosed Short-term Investments for 10 consecutive years, with $3.3 billion as the latest value for Q1 2026.

  • For Q1 2026, Short-term Investments fell 24.24% year-over-year to $3.3 billion; the TTM value through Mar 2026 reached $3.3 billion, down 24.24%, while the annual FY2025 figure was $3.2 billion, 37.15% down from the prior year.
  • Short-term Investments hit $3.3 billion in Q1 2026 for Moderna, up from $3.2 billion in the prior quarter.
  • Across five years, Short-term Investments topped out at $6.7 billion in Q4 2022 and bottomed at $3.2 billion in Q4 2025.
  • Average Short-term Investments over 5 years is $4.9 billion, with a median of $5.1 billion recorded in 2022.
  • Year-over-year, Short-term Investments skyrocketed 120.98% in 2022 and then tumbled 37.15% in 2025.
  • Moderna's Short-term Investments stood at $6.7 billion in 2022, then decreased by 14.93% to $5.7 billion in 2023, then dropped by 10.51% to $5.1 billion in 2024, then tumbled by 37.15% to $3.2 billion in 2025, then increased by 2.9% to $3.3 billion in 2026.
  • According to Business Quant data, Short-term Investments over the past three periods came in at $3.3 billion, $3.2 billion, and $3.4 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.